ALG3-CDG (CDG-Id): clinical, biochemical and molecular findings in two siblings

Mol Genet Metab. 2013 Sep-Oct;110(1-2):170-5. doi: 10.1016/j.ymgme.2013.05.020. Epub 2013 Jun 7.

Abstract

Congenital disorders of glycosylation (CDG) represent an expanding family of metabolic disorders with a wide range of biochemical, molecular and clinical phenotypes. ALG3-CDG (CDG-Id), due to a defect in endoplasmic reticulum (ER) mannosyltransferase VI, is one of the less common types of CDG-I. We describe two Vietnamese siblings with confirmed ALG3-CDG (CDG-Id) by molecular testing. As far as we are aware, they are the oldest reported patients in the literature at 15 and 21years. They share similar clinical features with previously reported patients including facial dysmorphism, severe psychomotor retardation, microcephaly, seizures, and gastrointestinal symptoms. Furthermore, our sibling pair highlights the intrafamilial variability, the natural clinical course of ALG3-CDG (CDG-Id) and the benefit of reassessing patients with undiagnosed and complex syndromes, particularly when they present with neurological deterioration.

Keywords: Cerebellar hypoplasia; Congenital disorders of glycosylation; Disability; Somnolence.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Congenital Disorders of Glycosylation / diagnostic imaging
  • Congenital Disorders of Glycosylation / genetics*
  • Congenital Disorders of Glycosylation / pathology
  • Endoplasmic Reticulum / enzymology
  • Endoplasmic Reticulum / genetics*
  • Humans
  • Infant
  • Male
  • Mannosyltransferases / genetics*
  • Microcephaly / diagnosis
  • Microcephaly / genetics*
  • Microcephaly / pathology
  • Mutation
  • Phenotype
  • Radiography
  • Siblings

Substances

  • ALG3 protein, human
  • Mannosyltransferases